Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.

PABA helps prevent gray hair and hair loss in mice.

This study found that idebenone-loaded nanoparticles (IB@NPs) improved stability, antioxidant activity, and wound healing capacity in vitro, suggesting potential applications in cosmetic and pharmaceutical fields.

In this retrospective study, baricitinib effectively improved alopecia areata in 78.7% of patients by the end of treatment, with significant hair regrowth observed, particularly in those with disease duration of four years or less, and showed no serious adverse events.

This article features a profile of the ABHRS/IBHRS as part of a series on regional societies and reports no new clinical findings.

This study found that certain molecular quantum descriptors can be directly correlated with the biological activity of benzo[c]quinolizin-3-ones, potentially aiding in the identification and design of active compounds.

This research investigates apoptosis and bcl 2 expression in hair follicles cultured with and without biotin, but it reports no new results.

The researchers reviewed multiple studies and found that baricitinib, a JAK inhibitor, generally improved the condition of patients with severe alopecia areata, with minimal side effects.

This review summarizes the mechanisms by which Plumbagin, a naphthoquinone derived from plants, may impact inflammation and explores its potential biological effects, highlighting areas that require further comprehensive research before considering it for therapeutic use.

In this case report, a young male developed bilateral pleural effusion and persistent fever after starting divalproex sodium for bipolar disorder, which improved upon discontinuation of the drug, suggesting a possible link between divalproex sodium and pleural effusion.

This study reported that depleting the pro-apoptotic protein Bax in hair follicle stem cells enables these cells to kill nearby viable cells by sequestering TNFα, which increases the stem cell pool and accelerates tissue regeneration, suggesting potential implications for therapies targeting tissue repair and cancer.

This review discusses recent advancements in omics and gene editing technologies for studying neuropeptides and receptors in fish, but reports no new experimental findings; the authors highlight the need for further research in this area.

This study reviewed baricitinib's efficacy and safety for treating alopecia areata and found that more patients achieved significant hair regrowth with baricitinib compared to placebo in two phase III trials. Mild to moderate side effects were reported, with additional study suggested for long-term effects.

This report describes a new case of syndromic ichthyosis caused by compound heterozygous mutations in AP1B1, detailing the associated clinical features and molecular consequences in the patient.

This study found that in patients with severe alopecia areata, those who responded early to baricitinib treatment typically had a lower baseline Severity of Alopecia Tool score, shorter disease duration, and higher erythrocyte sedimentation rate, suggesting these factors may predict therapeutic success.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

In this case study, a 55-year-old male farmer from Nepal with a kerion barbae in the beard region showed complete resolution after initiating oral itraconazole, highlighting the potential for misdiagnosis when bacterial superinfection complicates dermatophyte infections.

This abstract does not report results but indicates that the supplementary material includes comprehensive methodology, additional results, statistical analyses, discussion, and limitations of the Alopecia Areata Relapse Study Group's findings as presented in the main manuscript.

This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.

This article summarizes a meeting of the American Board of Hair Restoration Surgery's Board of Directors to discuss future plans, but does not report new experimental results.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

The researchers reported that altering auxin storage and conversion pathways in Arabidopsis and maize affects auxin levels and plant development, with implications for overall auxin homeostasis and interactions with gibberellic acid in seed germination.

This case report describes a 54-year-old Saudi woman with systemic lupus erythematosus and severe alopecia, where conventional treatments were ineffective. When belimumab was ineffective, baricitinib led to significant improvement in her condition, suggesting further research is needed to evaluate baricitinib's role in managing SLE.

This study aimed to describe the distribution of eyebrow and eyelash hair loss in patients with varying severities of scalp hair loss from alopecia areata but does not report results.

This case study reported that Ayurvedic treatment using Pracchana and Bibhitaki Lepa significantly improved symptoms of alopecia areata in a 41-year-old woman, reducing patch size and hair fall.

In this case study, an 8-year-old boy with alopecia totalis experienced significant hair regrowth after baricitinib treatment, suggesting KRT74 variants may influence immune dysregulation in this condition.

This study found that while biotin treatment improves clinical and biochemical symptoms in patients with biotinidase deficiency, some experience lasting neurological damage, and it is uncertain if early treatment can prevent this.

This research aims to address gaps in understanding alopecia areata by evaluating the real-world effectiveness and safety of baricitinib, identifying predictors of therapeutic response, and exploring the long-term impact on life quality, including sexual health. Results are not reported in the abstract.

In a retrospective multicenter cohort study, this research observed that baricitinib was effective and well-tolerated in treating adult patients with alopecia areata, including those with severe cases, showing promise in improving outcomes over a 12-month period with manageable side effects.

This study reports the cloning and expression details of two new human type II keratins, K6irs3 and K6irs4, in the hair follicle's inner root sheath, suggesting a distinct functional role related to hair structure.